According to GlobalData’s company profile on Bicycle Therapeutics, nanoparticle drug conjugates was a key innovation area identified from patents. Bicycle Therapeutics‘s grant share as of June 2023 was 1%. Grant share is based on the ratio of number of grants to total number of patents.
A recently filed patent (Publication Number: US20230181749A1) describes a pharmaceutical composition for the treatment of advanced solid tumor malignancies associated with Nectin-4-expression. The composition includes BT8009, or a pharmaceutically acceptable salt thereof, along with a pharmaceutically acceptable excipient or carrier. The excipient or carrier can be selected from a buffering agent, a stabilizer or cryoprotectant, and a surfactant.
The buffering agent in the composition is histidine, while the stabilizer or cryoprotectant is sucrose. The surfactant used is Polysorbate 20. Additionally, the composition may also include a pH adjusting agent, such as hydrochloric acid.
The pharmaceutical composition can be in the form of a solid lyophilized powder or a liquid formulation with water. The specific composition includes BT8009, histidine, sucrose, and Polysorbate 20 in specific ratios. For example, the composition may contain about 21.2 mg of BT8009, 27.8 mg of histidine, 318 mg of sucrose, and 1.06 mg of Polysorbate 20.
The patent also describes a method for treating advanced solid tumor malignancies associated with Nectin-4-expression. The method involves intravenously administering the pharmaceutical composition to the patient. The advanced solid tumor malignancies can include Non-Small-Cell Lung Cancer (NSCLC), ovarian cancer, Triple-Negative Breast Cancer (TNBC), gastric/upper Gastrointestinal (GI) cancer, Pancreatic cancer, and Urothelial cancer.
The pharmaceutical composition can be administered once every 7 days at a dose of about 2.5, 5.0, 7.5, 10.0, 13.0, or 17.0 mg/m2. The administration is done via an intravenous (IV) infusion lasting about 60 minutes. In some cases, the method may also involve administering Nivolumab, another medication used in cancer treatment, via an IV infusion lasting about 30 minutes.
Overall, this patent describes a pharmaceutical composition and method for treating advanced solid tumor malignancies associated with Nectin-4-expression. The composition includes specific ratios of BT8009, histidine, sucrose, and Polysorbate 20, and can be administered intravenously to patients. The method may also involve the use of Nivolumab in combination with the pharmaceutical composition.
To know more about GlobalData’s detailed insights on Bicycle Therapeutics, buy the report here.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
Source link
#Patent #Pharmaceutical #Composition #BT8009 #Excipient
